Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy

H. B. Lee; H. Noh; J. Y. Seo; M. R. Yu; H. Ha

doi:10.1038/sj.ki.5002388

Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy

H. B. Lee, H. Noh, J. Y. Seo, M. R. Yu, H. Ha

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such as through histone acetylation, is a fundamental phenomenon in eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory and those of others demonstrating antifibrotic and renoprotective effect of HDAC inhibitors in diabetic kidneys, and the possible mechanisms including the role of reactive oxygen species. HDAC inhibitors may prove to be a novel class of multitarget agents in the treatment of diabetic nephropathy.

Original language	English
Pages (from-to)	S61-S66
Journal	Kidney International
Volume	72
Issue number	SUPPL. 106
DOIs	https://doi.org/10.1038/sj.ki.5002388
State	Published - Aug 2007

Keywords

Diabetic complications
Fibrosis
Histone acetylation
Histone deacetylase inhibitor
Hsp90
Reactive oxygen species

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.ki.5002388

Cite this

@article{3ebbcb9725e9471b9abb957cb1ab4ec1,

title = "Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy",

abstract = "Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such as through histone acetylation, is a fundamental phenomenon in eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory and those of others demonstrating antifibrotic and renoprotective effect of HDAC inhibitors in diabetic kidneys, and the possible mechanisms including the role of reactive oxygen species. HDAC inhibitors may prove to be a novel class of multitarget agents in the treatment of diabetic nephropathy.",

keywords = "Diabetic complications, Fibrosis, Histone acetylation, Histone deacetylase inhibitor, Hsp90, Reactive oxygen species",

author = "Lee, {H. B.} and H. Noh and Seo, {J. Y.} and Yu, {M. R.} and H. Ha",

year = "2007",

month = aug,

doi = "10.1038/sj.ki.5002388",

language = "English",

volume = "72",

pages = "S61--S66",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "SUPPL. 106",

}

TY - JOUR

T1 - Histone deacetylase inhibitors

T2 - A novel class of therapeutic agents in diabetic nephropathy

AU - Lee, H. B.

AU - Noh, H.

AU - Seo, J. Y.

AU - Yu, M. R.

AU - Ha, H.

PY - 2007/8

Y1 - 2007/8

N2 - Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such as through histone acetylation, is a fundamental phenomenon in eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory and those of others demonstrating antifibrotic and renoprotective effect of HDAC inhibitors in diabetic kidneys, and the possible mechanisms including the role of reactive oxygen species. HDAC inhibitors may prove to be a novel class of multitarget agents in the treatment of diabetic nephropathy.

AB - Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such as through histone acetylation, is a fundamental phenomenon in eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory and those of others demonstrating antifibrotic and renoprotective effect of HDAC inhibitors in diabetic kidneys, and the possible mechanisms including the role of reactive oxygen species. HDAC inhibitors may prove to be a novel class of multitarget agents in the treatment of diabetic nephropathy.

KW - Diabetic complications

KW - Fibrosis

KW - Histone acetylation

KW - Histone deacetylase inhibitor

KW - Hsp90

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=34547431097&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5002388

DO - 10.1038/sj.ki.5002388

M3 - Article

C2 - 17653213

AN - SCOPUS:34547431097

SN - 0085-2538

VL - 72

SP - S61-S66

JO - Kidney International

JF - Kidney International

IS - SUPPL. 106

ER -

Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this